A randomized, open-label study of MabThera [rituximab] maintenance therapy compared with no further therapy after a brief induction with chemotherapy plus MabThera on failure-free survival in treatment-naive elderly patients with advanced follicular lymphoma.

Trial Profile

A randomized, open-label study of MabThera [rituximab] maintenance therapy compared with no further therapy after a brief induction with chemotherapy plus MabThera on failure-free survival in treatment-naive elderly patients with advanced follicular lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Dexamethasone; Fludarabine; Mitoxantrone
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Aug 2013 Results published in the Journal of Clinical Oncology.
    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top